-
Article
Open AccessHigh expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker
Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences clinical decision-making between treatment and active surveillance. The development of...
-
Article
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-a...
-
Article
Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth
The complement system is a major component of the innate immune system that works through the cytolytic effect of the membrane attack complex (MAC). Complement component 7 (C7) is essential for MAC assembly an...
-
Article
Open AccessStromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity
Cancer-associated fibroblasts (CAFs) mediate an immunosuppressive effect, but the underlying mechanism remains incompletely defined. Here we show that increasing prostatic stromal Foxf2 suppresses the growth and ...
-
Article
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
A Correction to this paper has been published: https://doi.org/10.1038/s41588-021-00786-2.
-
Article
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studie...
-
Article
Open AccessProspective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Genomic classifiers (GC) have been shown to improve risk stratification post prostatectomy. However, their clinical benefit has not been prospectively demonstrated. We sought to determine the impact of GC test...
-
Article
The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study
The prostate biopsy pathology report represents a critical document used for decision-making in patients diagnosed with prostate cancer, yet the content exceeds the health literacy of most patients. We sought ...
-
Article
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)
For men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer. This study examined the association of urinary PCA3 and TMPRSS2:ERG (...
-
Article
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
In the version of this article initially published, the name of author Manuela Gago-Dominguez was misspelled as Manuela Gago Dominguez. The error has been corrected in the HTML and PDF version of the article.
-
Article
Improving the Specificity of PSA Screening with Serum and Urine Markers
Prostate cancer remains a significant public health burden. In order to decrease the morbidity and mortality associated with prostate cancer, serum prostate-specific antigen (PSA) screening has been used since th...
-
Article
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Genome-wide association studies (GWAS) and fine-map** efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array...
-
Article
Open AccessFine-map** of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate ...
-
Article
Open AccessInternational Society for Therapeutic Ultrasound Conference 2016
-
Article
Open AccessEpigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy
Identifying the subset of patients with clinically localized prostate cancer (PCa) at the highest risk of recurrence remains challenging, and better prognostic markers are needed. Gleason score is the best pre...
-
Article
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist
Active surveillance (AS) is an important management option for men with low-risk, clinically localized prostate cancer. The clinical parameters for patient selection and definition of progression for AS protoc...
-
Article
Open AccessA preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results
A small pre-test study was conducted to ascertain potential harm and anxiety associated with distributing information about possible cancer treatment options at the time of biopsy, prior to knowledge about a d...
-
Article
Prostate cancer risk stratification by genotype and PSA
The use of PSA testing as a screening tool for prostate cancer is limited by its low specificity. New data offer insight into how genotypic information might be incorporated into PSA screening approaches to en...
-
Article
New and novel markers for prostate cancer detection
The detection and treatment of prostate cancer was dramatically altered with the advent of the prostate-specific antigen (PSA), and its usefulness particularly in following patients after radical prostatectomy...
-
Article
The basic biochemistry and molecular events of hormone therapy
Data regarding the molecular response of prostate cancer to hormone therapy continue to emerge, identifying a complex network of autocrine and paracrine signaling events mediating the tumor response to androge...
